{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiebthkd3z5pdjyynv3dpjrblyweoaxewwmuwm2m5gryija5n5iuvq",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mendjg4zwbi2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibmnovnhkmkr4bbgbbexnv7todqo6rli3i56jr4hc43zivdcrs34y"
    },
    "mimeType": "image/jpeg",
    "size": 23523
  },
  "path": "/2026/02/12/novel-anti-fibrotic-drug-ak3280-cleared-by-fda-to-initiate-phase-2-proof-of-concept-clinical-trial-in-ipf/",
  "publishedAt": "2026-02-12T04:18:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SHANGHAI, Feb. 12, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase 2 proof-of-concept (PoC) […]",
  "title": "Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF"
}